Cardiff Oncology Inc. Stock News

Cardiff Oncology (CRDF) recorded a new 52-week low today in reaction to the company’s newly-shared data from a Phase 1b/2 trial for onvansertib/ standard-of-care ((SOC)) combo in…

Zogenix ZGNX +68%. Vivos Therapeutics VVOS +33%. Cardiff Oncology CRDF -24%. Yumanity Therapeutics YMTX -17%.

Cardiff Oncology (CRDF) is trading ~16.3% lower in the pre-market after updating data from its lead clinical program for onvansertib/ standard-of-care ((SOC)) FOLFIRI/bevacizumab.The

Cardiff Oncology Inc (NASDAQ: CRDF) posted new data from Phase 1b/2 trial of onvansertib combined with standard-of-care (SOC) FOLFIRI/bevacizumab for second-line KRAS-mutated metastatic colorectal

Biotech stocks posted losses for the third straight week, as the sector reacted to broader market weakness and announcements out of the 2022 JPMorgan Healthcare conference. Swiss biotech Molecular Partners AG (NASDAQ: MOLN ) was among the best-performing stocks in the past week following the release of positive Phase 2 data for partnered COVID-19 antiviral treatment. Ahead of the fourth-quarter reporting season, preannouncements continued to dominate biotech news. The week also witnessed the debut of Hillstream Biopharma, Inc. (NASDAQ: HILS ) following its initial public offering, which raised $15 million in gross proceeds for the oncology-focused company. Here are the key catalysts that could move stocks in the unfolding week: Conferences Winter Clinical Dermatology Conference: Jan. 14-19, in Koloa, Hawaii American Society of Clinical Oncology, or ASCO, Gastrointestinal Cancers Symposium: Jan. 20 22 (hybrid format, in San Francisco, California & virtual) Société Francophone du Nerf Périphérique, or SFNP, Annual Meeting: Jan. 21-22, in Paris, France Clinical Data Readouts/Presentations Dermatology Conference Presentations ASLAN Pharmaceuticals Limited (NASDAQ: ASLN ): results from the dose escalation portion of the completed Phase 1b Proof-of-Concept study of ASLAN004 in atopic dermatitis ASCO-GI Conference Presentations Cardiff Oncology, Inc. (NASDAQ: CRDF ): updated data from its lead clinical program in KRAS-mutated metastatic colorectal cancer; Ahead of the presentation, the company is

Cardiff Oncology Inc (CRDF) shares closed today 10.2% higher than it did at the end of yesterday. The stock is currently up 9.5% year-to-date, down 64.1% over the past 12 months, and down 96.0% over the past five years. Today, the Dow Jones Industrial Average rose 0.5%, and the S&P 500 rose 0.9%. Trading Activity Shares traded as high as $7.29 and as low as $5.92 this week.Shares closed 63.3% below its 52-week high and 48.6% above its 52-week low.Trading volume this week was 10.5% lower than the 10-day average and 17.2% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -539.8% The company's stock price performance over the past 12 months lags the peer average by 111.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

These three stocks are poised for a major breakout in 2022.

Equities research analysts predict that Cardiff Oncology, Inc. (NASDAQ:CRDF) will report sales of $70,000.00 for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Cardiff Oncologys earnings. The lowest sales estimate is $50,000.00 and the highest is $90,000.00. Cardiff Oncology posted sales of $120,000.00 during the same quarter last year, []

During the last session, Cardiff Oncology Inc. (NASDAQ:CRDF)s traded shares were 0.93 million, with the beta value of the company hitting 1.65. At the end of the trading day, the stocks price was $6.14, reflecting an intraday gain of 10.23% or $0.57. The 52-week high for the CRDF share is $23.15, that puts it down Is Cardiff Oncology Inc.s (NASDAQ: CRDF) 9.25% Gain This Week Telling Us Something New? Read More »

Cardiff has one asset, onvansertib, a PLK1 inhibitor which has performed well in the clinic thus far in second line KRAS-mutated mCRC.

BioNTech (NASDAQ:BNTX) and Cardiff Oncology (NASDAQ:CRDF) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk. Institutional & Insider Ownership 14.3% of BioNTech shares are owned by institutional investors. Comparatively, 67.0% of Cardiff []

Cardiff Oncology (NASDAQ:CRDF) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends and risk. Profitability This table compares Cardiff Oncology and Black Diamond Therapeutics net margins, return on []

BioNTech (NASDAQ:BNTX) and Cardiff Oncology (NASDAQ:CRDF) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability and earnings. Profitability This table compares BioNTech and Cardiff Oncologys net margins, return on equity and return on assets. []

Cardiff Oncology Inc. (NASDAQ:CRDF) shares, rose in value on Wednesday, 11/24/21, with the stock price up by 6.51% to the previous days close as strong demand from buyers drove the stock to $5.73. Actively observing the price movement in the last trading, the stock closed the session at $5.38, falling within a range of $5.21 Is Cardiff Oncology Inc. (NASDAQ: CRDF) A Stock A New Investor Should Consider Now? Read More »

Maxim Group reissued their buy rating on shares of Cardiff Oncology (NASDAQ:CRDF) in a report published on Friday, Analyst Price Targets reports. The firm currently has a $24.00 target price on the stock. Other equities analysts have also recently issued research reports about the stock. HC Wainwright reaffirmed a buy rating and set a $26.00 []